Bree Foster, PhD
Bree Foster is a science writer at Drug Discovery News with over 2 years of experience at Technology Networks, Drug Discovery News, and other scientific marketing agencies. She holds a PhD in comparative and functional genomics from the University of Liverpool and enjoys crafting compelling stories for science.
Articles by Bree Foster, PhD
| 4 min read
As drug discovery adopts more human-relevant models and complex biologics, it’s increasingly important that reagents are more consistent, better characterized, and fit for purpose.
| 6 min read
Long framed as a gynecological condition, PMOS is now understood as a multisystem disorder with metabolic, psychological, and cardiovascular consequences.
| 4 min read
Study demonstrates that computationally-designed miniproteins can modulate GPCR activity in native cellular environments, expanding access to a major drug target family.
| 3 min read
An integrated workflow brings charge and size analysis together for faster, more informative bispecific antibody characterization.
| 4 min read
SLAS Europe 2026 showcased growing realism around AI in drug discovery, with attention shifting toward data quality, interoperability, and lab execution.
| 6 min read
NAMs are increasingly used to de-risk preclinical development decisions, yet their broader impact on toxicology will depend on whether they are required or simply encouraged by regulators.
| 5 min read
A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases.
| 3 min read
This year’s New Product Award winners reflect growing demand for tools that improve throughput, reproducibility, and hands-free operation in the lab.
| 5 min read
A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system.
| 5 min read
Endometriosis is still largely managed with pain relief, hormones, and surgery, but a new precision peptide therapy seeks to directly target the underlying lesion biology.
| 5 min read
Despite rapid therapeutic advances in sickle cell disease, from red blood cell exchange to gene therapies, delivery remains constrained by infrastructure, geography, and care fragmentation.
| 6 min read
Despite growing regulatory acceptance, widespread adoption of NAMs depends on workflow integration, reproducibility, and perceived risk in industry decision-making.
